Multiprofile Hospital For Active Treatment Blagoevgrad AD
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The department is conducting research aimed at lowering cardiovascular risk by targeting abnormal lipid profiles. Trials evaluate the safety of new agents for severe hypertriglyceridemia and the effectiveness of lipoprotein(a) reduction in preventing major adverse cardiac events.
- Evaluation of a novel therapy to reduce triglyceride levels
- Assessment of lipoprotein(a) lowering on heart attack and stroke outcomes
- Long‑term safety monitoring of cardiovascular agents
The Multiprofile Hospital For Active Treatment Blagoevgrad AD supports these studies to improve treatment options for patients with cardiovascular disease.
Nervous System Diseases
Research in this area focuses on disease‑modifying therapies for multiple sclerosis and acute stroke care. Studies compare new monoclonal antibodies with existing treatments and explore strategies to enhance reperfusion after an acute ischemic stroke.
- Testing a novel antibody to delay disability progression in secondary progressive MS
- Comparing efficacy of a new drug with standard therapy in relapsing MS
- Optimizing reperfusion techniques to improve neurological outcomes after stroke
These investigations aim to provide better therapeutic options for patients suffering from nervous system diseases at the Blagoevgrad site.
Respiratory Tract Diseases
The hospital is evaluating long‑term safety and tolerability of innovative treatments for chronic obstructive pulmonary disease. The focus is on maintaining lung function and reducing exacerbations in patients with moderate to severe disease.
- Extended safety assessment of a novel COPD therapy
- Impact of treatment on frequency of COPD exacerbations
- Monitoring respiratory outcomes over multiple years
This work supports improved management strategies for individuals with respiratory tract diseases in the region.
Nutritional and Metabolic Diseases
Studies target metabolic disorders characterized by elevated blood lipids. Researchers are testing the safety of a new agent for severe hypertriglyceridemia and measuring its effect on fasting triglyceride reduction.
- Safety evaluation of a subcutaneous lipid‑lowering drug
- Effectiveness in decreasing fasting triglyceride levels
- Potential to lower metabolic risk associated with high triglycerides
The goal is to expand therapeutic choices for patients with nutritional and metabolic diseases at this clinical site.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
The center explores inherited lipid abnormalities and their early clinical manifestations. Research includes genetic risk profiling and evaluating preventive interventions for families with hereditary disorders.
- Identification of genetic markers linked to lipid metabolism disorders
- Assessment of early treatment strategies in hereditary conditions
- Long‑term follow‑up of patients with congenital metabolic abnormalities
By addressing hereditary lipid disorders, the hospital aims to improve outcomes from birth through adulthood.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 13 of 14 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1AstraZeneca AB1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Multiprofile Hospital For Active Treatment Blagoevgrad AD
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults with Moderate or Severe Diabetic Foot Infections | Micurx Pharmaceuticals Inc. | Phase III | Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Isis 678354 Sodium Salt | 2 | Unknown | 2022-03-08 | 2023-07-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.